Cannabics Pharmaceuticals has announced that it has filed an international patent application with the PCT authorities on methods for testing which cannabinoids or combinations of cannabinoids are likely be effective in individual patients.

The determination is made by testing the effects of cannabinoids on CTCs (Circulating Tumor Cells) and biopsies of cancer patients. The integrated approach brings together cannabinoids research, Genetic markers, CTC counting and detection methods, and a drug sensitivity test for cannabinoids developed by Cannabics Pharmaceuticals. This unique method expands the company's proprietary technology of developing a more precise tool for personalization of cannabinoids based medicine as well as accelerating drug discovery.

Cannabics Pharmaceuticals Inc., a US based public company, is dedicated to the development of personalized anti-cancer and palliative treatments.